Advertisement

Topics

AstraZeneca Presents Imfinzi (durvalumab) Plus tremelimumab Combination Data at AACR Annual Meeting

19:39 EDT 16 Apr 2018 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
Phase Ib Study 006 long-term follow-up shows clinical activity in PD-L1 greater than or equal to 25% and less than 25% groups in 2nd-line non-small cell lung cancer Phase I Study 10 data shows clinical activity with combination treatment in 2nd-line...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca Presents Imfinzi (durvalumab) Plus tremelimumab Combination Data at AACR Annual Meeting"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...